Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors

被引：33

作者：

Letavic, Michael A.

Keith, John M.

Jablonowski, Jill A.

Stocking, Emily M.

Gomez, Leslie A.

Ly, Kiev S.

Miller, Jennifer M.

Barbiera, Ann J.

Bonaventure, Pascal

Boggs, Jamin D.

Wilson, Sandy J.

Miller, Kirsten L.

Lord, Brian

McAllister, Heather M.

Tognarelli, D. J.

Wu, Jiejun

Abad, Marta C.

Schubert, Carsten

Lovenberg, Timothy W.

Carruthers, Nicholas I.

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA

[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Exton, PA 19341 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 04期

关键词：

histamine; histamine H-3 antagonists; serotonin; serotonin reuptake inhibitors; tetrahydroisoquinolines;

D O I：

10.1016/j.bmcl.2006.11.036

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of novel 4-aryl-1,2,3,4-tetrahydroisoquinoline-based histamine H-3 ligands that also have serotonin reuptake transporter inhibitor activity is described. The synthesis, in vitro biological data, and select pharmacokinetic data for these novel compounds are discussed. (c) 2006 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1047 / 1051

页数：5

相关论文

共 23 条

[1] A new class of diamine-based human histamine H3 receptor antagonists:: 4-(aminoalkoxy)benzylamines [J].

Apodaca, R ;

Dvorak, CA ;

Xiao, W ;

Barbier, AJ ;

Boggs, JD ;

Wilson, SJ ;

Lovenberg, TW ;

Carruthers, NI .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (18) :3938-3944

[2] Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist [J].

Barbier, AJ ;

Berridge, C ;

Dugovic, C ;

Laposky, AD ;

Wilson, SJ ;

Boggs, J ;

Aluisio, L ;

Lord, B ;

Mazur, C ;

Pudiak, CM ;

Langlois, X ;

Xiao, W ;

Apodaca, R ;

Carruthers, NI ;

Lovenberg, TW .

BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (05) :649-661

[3] Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis [J].

Beasley, CM ;

Koke, SC ;

Nilsson, ME ;

Gonzales, JS .

CLINICAL THERAPEUTICS, 2000, 22 (11) :1319-+

[4]

CARRUTHERS NI, 2006, Patent No. 2006066197

[5] 4-Phenoxypiperidines:: Potent, conformationally restricted, non-imidazole histamine H3 antagonists [J].

Dvorak, CA ;

Apodaca, R ;

Barbier, AJ ;

Berridge, CW ;

Wilson, SJ ;

Boggs, JD ;

Xiao, W ;

Lovenberg, TW ;

Carruthers, NI .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :2229-2238

[6] Residual symptoms in depression: An emerging therapeutic target [J].

Fava, GA ;

Fabbri, S ;

Sonino, N .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (06) :1019-1027

[7] Predictors of efficacy in depression prevention programmes -: Meta-analysis [J].

Jané-Llopis, E ;

Hosman, C ;

Jenkins, R ;

Anderson, P .

BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 :384-397

[8] Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy [J].

Jasinski, DR ;

Kovacevic-Ristanovic, R .

CLINICAL NEUROPHARMACOLOGY, 2000, 23 (03) :149-156

[9]

KEITH JM, IN PRESS BIOORG MED

[10]

Letavic MA, 2006, PROGR MED CHEM, V44, P181, DOI 10.1016/S0079-6468(05)44405-7